Strategy is to Screen and Qualify Viable Applicants/Patients for Treatment in DR Through Regenerative BioScience, Inc.

Treatments have already commenced

SARASOTA, Fla., 2014 (GLOBE NEWSWIRE) — Caribbean International Holdings CIHN +45.10% through its subsidiary, Regenerative BioScience, Inc., (“RBS”) previously announced on May 2, 2014, that it had appointed Dr. Leonel Liriano as its Medical Director, today announced, in a further development, that via the Company’s new website ( http://www.regenerativebioscience.com/index.html ) is now fully operational and it has begun processing initial requests for its no-cost cost complimentary consultations regarding the applicant’s suitability to qualify for Company’s revolutionary stem cell procedures.

Adult stem cells work as the repairmen of the body by replenishing and regenerating damaged tissues and cells. Certain conditions have shown marked improvement when treated with adult stem cells taken from the patient’s own body. Regenerative BioScience is a revolution in healthcare using a patient’s own adult stem cells. There is little to no risk of rejection when a patient’s own stem cells are used.

As anticipated, RBS is averaging 3 to 5 applicants per week during its initial rollout period. Eight patients have now been fully qualified, and three are ready to go to the DR in the next two weeks, for their procedures to commence under the guidance of Dr. Liriano.

Each application or health record is initially processed and then sent to Dr. Liriano for his personal diagnosis. After Dr. Loriano’s diagnosis, then representatives of both CIHN and RBS make the arrangements, as per Dr. Liriano instructions, for commencement of treatment.

Dr. Liriano, as previously reported, had treated well known athlete, Bartolo Colon, who was out of baseball for nearly 2 years because of a serious shoulder injury, but returned to the sport and became an All-Star thanks to a stem cell procedure where stem cells were taken from his body and then re-injected into his shoulder by Dr. Liriano. This injury previously may have required surgery to be repaired or the player would be forced into early retirement.

Steven Swank, Chairman and CEO of Caribbean International Holdings, stated, “We are happy with the number of applications we have received during this ramp-up period and the patients we have treated have shown great improvement, and are very satisfied with their progress.”

Swank went on to say: “We at CIHN and RBS know that stem cells can work wonders and are pleased that our web site admissions program is operational, and our patient coordinators are doing their job. I am personally very gratified to announce eight patients have now been fully qualified, and three are ready to go to the DR in the next two weeks, for their procedures to commence under the guidance of Dr. Liriano. Since our contract was signed with Dr. Liriano on February 1st in New York, our day-to-day business has become more exciting for all of us here at CIHN, and the promise of great business to come seems inevitable to myself and our employees.”

On another matter, the Company announced the opening of new treatment locations in Guadalajara, Mexico, and Cabo St Lucas, and is also negotiating to install a proprietary lab in Santa Domingo, Dominican, Republic.

Additionally the Company announced that on May 15th to the 17th, Rafael Gonzalez who is on the Company’s advisory board, will be a guest speaker at the 22nd Annual World Congress on ANTI-AGING, REGENERATIVE & AESTHETIC MEDICINE, in Orlando, Florida

About The Company:

Caribbean International Holdings, Inc. is a holding company for Regenerative BioScience, Inc. (“RBSI”). The Company subsidiary RBSI is focused on helping individuals protect and ensure their future quality of life through Adult Stem Cell Incubation and the practice of regenerative medicine in the United States and the Dominican Republic. RBSI’s mission is not only to allow patients to store their Stem Cells for future use, but also perform patient funded stem cell therapies for degenerative diseases such as MS, Arthritis, Degenerative Heart Diseases, Diabetes and a host of experimental therapies in the brain trauma disease sector including CTE. The goal is to become a global leader in establishing protocols that can be patented and utilized to heal patients around the world.

For more information go to: http://www.regenerativebioscience.com/index.html

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available on at http://www.sec.gov .

Related story:

World-renown stem cell physician appointed as medical director for Regenerative BioScience

SARASOTA, Fla., May 02, 2014 (GLOBE NEWSWIRE via COMTEX) —

Caribbean International Holdings CIHN +54.55% through its subsidiary, Regenerative BioScience, has appointed Dr. Leonel Liriano as its Medical Director.

Leonel Francisco Liriano Espinal is a graduate of the Medical School of Medicine Technical University of Santiago (UTESA). Dr. Liriano has specialized as an intensive care physician at St. Joseph Hospital in the city of Santiago de Chile, and has also been prepared in Clinical Nutrition for Critical Patient in the Auxilio Mutuo Hospital, in the city of Santurce, Puerto Rico, as well as studied Intensive Post-operative Cardiovascular at Cedars Hospital in the City of Miami, Florida and trainings in Neurocritical care in NYU Hospital, New York City.

Twelve years ago while talking to a surgeon who practiced in Germany, Dr. Liriano, who is professor of cardiology and intensive care at the Technological University of Santiago (UTES), became interested in the process of cell therapy and how this could serve as hope to treat diseases without possibility of cure. Since then, Dr. Liriano along with his team of doctors from different specialties has successfully applied the stem cell-based therapy to more than 1000 people. This includes 200 sports figures; with the most prominent being baseball player Bartolo Colon for whom he was the lead physician.

Bartolo Colon was out of baseball for nearly 2 years because of a serious shoulder injury, but returned to the sport and became an All-Star thanks to a stem cell procedure where stem cells were taken from his body and then re-injected into his shoulder by Dr. Liriano. This injury previously may have required surgery to be repaired or the player would be forced into early retirement. This life changing procedure may now have the potential to extend athletes careers and shorten rehabilitation time.

The Dr. Liriano is proud to belong to a generation that has much to offer. He is considered as a dynamic professional and owner of a gift that inspires others to make the most of their potential and one of the pioneers of cell therapy in the City of Santiago. He is convinced that in the not too distant future most diseases will be treated with this therapy.

Steven Swank, Chairman and CEO of Caribbean International Holdings, stated “I have received stem cells myself 3 years ago and am a true believer in its potential after seeing my health improvements. Dr. Liriano shares our vision of helping to improve quality of life and we could not be more excited to have someone with this extensive experience and knowledge in this field join as our Medical Director.”

FORWARD-LOOKING STATEMENT

This report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation.

IMAGE: www.allthingsstemcell.com